Evercore ISI cuts Aflac stock price target on capital concerns

Evercore ISI cut Aflac’s price target to $109 from $112 while keeping an Underperform rating, citing aggressive $1 billion buybacks, but also declining excess capital levels and lower capital ratios in Japan and the U.S. The article also notes mixed fourth-quarter 2025 results, with EPS of $1.57 missing the $1.70 estimate while revenue of $4.87 billion beat the $4.28 billion consensus. Overall, the piece is a mixed analyst-and-earnings update with limited but notable stock-level impact.

Analysis

Aflac’s setup is less about near-term earnings momentum and more about the optionality embedded in a capital-rich balance sheet. The incremental buyback is supportive, but the bigger point is that management is still behaving as if the stock is cheap relative to intrinsic capital generation, while the market is fixated on quarterly optics. That creates a mismatch: if reserve releases come through as expected, the equity can re-rate on a cleaner, higher-ROE narrative even without dramatic top-line growth.

The main second-order risk is that capital return can mask deteriorating underwriting quality for a few quarters before it shows up in benefit ratios and reserve assumptions. A modestly worse Japan claims trajectory would matter more than the headline capital ratios, because it would force the market to discount the durability of future buybacks. In that sense, the next actuarial review is the real catalyst window: a favorable reserve release can compress the bear case quickly, while a small miss could unwind the valuation support.

Consensus appears to be extrapolating conservatism into a persistent cushion, but the market may be underpricing how quickly a capital-light insurer can trade on the marginal change in reserve credibility rather than absolute solvency. If management continues repurchasing stock at this pace and the review surprises positively, the stock can work higher over the next 1-2 quarters even with muted multiple expansion. Conversely, if the release is smaller than expected, the downside is less about solvency and more about the multiple de-rating from a diminished capital deployment story.

Key Decisions for Investors

• Short-dated call spread on AFL into the next actuarial/review window: buy 3-6 month calls financed by selling a higher strike to express a rerating if reserve releases beat expectations; risk/reward favors upside surprise over a large downside unless claims worsen materially.
• If already long AFL, trim only on a failed reserve-release catalyst rather than on capital-ratio headlines; those metrics are lagging and the stock should be judged on underwriting credibility over the next 1-2 quarters.
• Pair trade: long AFL / short a higher-quality insurer with less capital-return optionality if you want to isolate re-rating from capital deployment; AFL’s edge is in buyback density and balance-sheet flexibility, not clean fundamental growth.
• For bearish exposure, wait for the post-review bounce and then use put spreads rather than outright shorting; the stock has downside protection from buybacks, so timing matters more than conviction.
• If the reserve review is favorable, add on the first 2-3% intraday pullback rather than chasing strength; the market typically underreacts initially to insurance reserve releases and then prices them in over several sessions.